Camizestrant Plus Ribociclib Shows Promise in Advanced Breast Cancer
new Breast Cancer Treatment Shows Promise in Early Trial
Camizestrant Plus Ribociclib Demonstrates Efficacy and Safety in Patients with Advanced Disease
Results from the SERENA-1 trial, presented at the 2024 San Antonio Breast Cancer Symposium (SABCS), offer hope for patients with advanced breast cancer. The phase 1 study investigated the combination of camizestrant,a next-generation oral selective estrogen receptor degrader (SERD),and ribociclib (Kisqali),a CDK4/6 inhibitor.
The trial focused on patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer, a subtype that often proves challenging to treat.
Researchers examined the safety and efficacy of two different ribociclib doses (400 mg and 600 mg) combined with 75 mg of camizestrant daily.
As of September 16, 2024, 60 patients had received the combination therapy. The median duration of treatment was 7.5 months for the 400 mg ribociclib arm and 5.6 months for the 600 mg arm.
Encouragingly, the study showed promising results:
Progression-Free Survival (PFS): Median PFS was 8.1 months in both the 400 mg and 600 mg ribociclib arms.
Objective Response Rate (ORR): ORR, which measures tumor shrinkage, was 11.1% in the 400 mg arm and 12.5% in the 600 mg arm.
* CBR24: This measure, indicating the percentage of patients with stable disease or tumor shrinkage for at least 23 weeks, was 55.6% in the 400 mg arm and 53.1% in the 600 mg arm.
importantly, the combination therapy demonstrated a favorable safety profile. The most common side effects were neutropenia (low white blood cell count), nausea, photopsia (seeing flashes of light), and sinus bradycardia (slow heart rate).”Camizestrant 75 mg in combination with either ribociclib 400 mg or 600 mg was well tolerated,” researchers noted. “The safety profile is comparable to camizestrant monotherapy and other CDK4/6 inhibitor combinations.”
These early findings suggest that camizestrant plus ribociclib could be a valuable new treatment option for patients with ER+/HER2– advanced breast cancer. Further research is underway to confirm these results and explore the long-term benefits of this promising combination.
Reference
Ruiz-Borrego M, Ruiz IV, Vaklavas C, et al., Results from SERENA-1 Parts K/L: A phase 1 study of the next-generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) in combination with ribociclib in women with ER-positive, HER2 negative advanced breast cancer, presented at the San Antonio Breast Cancer Symposium, December 10-13, 2024, San Antonio, Texas. PS7-08.
Please provide me wiht the text you would like me to summarize. I need the content in order to create a summary for you. 😊